Effect of Ranitidine and Sucralfate on the incidence of ventilator-associated pneumonia

Comparing the effect of Ranitidine and Sucralfate on the incidence of ventilator-associated pneumonia in ICU patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017080835577N1

Enrollment

148

Registered

2017-10-10

Start date

2014-08-27

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ventilator-associated pneumon. Other postprocedural respiratory disorders

Interventions

Intervention 1: Tablet Sucralfate 1 gram, 1 gram per 6 hours, for 10 days, made by Kimidaru co. Intervention 2: Tablet Ranitidine 150 mg, 150 mg every 8 hours, for 10 days, made by Kimidaru co.

Treatment - Drugs

Tablet Sucralfate 1 gram, 1 gram per 6 hours, for 10 days, made by Kimidaru co.

Tablet Ranitidine 150 mg, 150 mg every 8 hours, for 10 days, made by Kimidaru co.

Eligibility

Sex/Gender

All

Age

14 Years to 74 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged between 15 and 75 years old ; men or women ; has the sofa score 4 to 10 at the time of admission; require intubation for more than 48 hours. Exclusion criteria : History of recent pulmonary infection or gastrointestinal bleeding; Early discharge of ICU ; Extubation less than 48 hours ; Patients Has any immunodeficiency.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Amount of serum ESR. Timepoint: Daily for 6 days. Method of measurement: Serum ESR test.;Amount of serum white blood cells. Timepoint: Daily for 6 days. Method of measurement: Cell blood count test.;Amount of arterial oxygen concentration. Timepoint: Daily for 6 days. Method of measurement: Arterial blood gas.;Type of Nasotracheal discharge. Timepoint: Daily for 6 days. Method of measurement: Nasotracheal discharge culture.;Incidence of VAP. Timepoint: Daily for 6 days. Method of measurement: culture of discharge.	—

Measure

Time frame

Amount of serum ESR. Timepoint: Daily for 6 days. Method of measurement: Serum ESR test.;Amount of serum white blood cells. Timepoint: Daily for 6 days. Method of measurement: Cell blood count test.;Amount of arterial oxygen concentration. Timepoint: Daily for 6 days. Method of measurement: Arterial blood gas.;Type of Nasotracheal discharge. Timepoint: Daily for 6 days. Method of measurement: Nasotracheal discharge culture.;Incidence of VAP. Timepoint: Daily for 6 days. Method of measurement: culture of discharge.

—

Secondary

Measure	Time frame
Amount of body temperature. Timepoint: Every 12 hours for 6 days. Method of measurement: With sub axillary thermometer.;Amount of serum cratinin. Timepoint: Daily for 10 days. Method of measurement: Serum cratinin test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmin Yousefelahi

Department of Anesthesiology, Rafsanjan University of Medical Sciences

ayousefelahi@rums.ac.ir+98 34 3281 2985

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026